{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:58:44Z","timestamp":1787313524478,"version":"build-2736575974"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RE\/18\/6\/34\u2009217"],"award-info":[{"award-number":["RE\/18\/6\/34\u2009217"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["FS\/MBPhD\/22\/28\u2009005"],"award-info":[{"award-number":["FS\/MBPhD\/22\/28\u2009005"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"United Kingdom Research and Innovation Strength in Places Fund","award":["SIPF00007\/1"],"award-info":[{"award-number":["SIPF00007\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Emerging antihypertensive drug classes offer new opportunities to manage hypertension; however, their long-term effects on cardiovascular, kidney, and metabolic (CKM) outcomes remain to be elucidated. This study aims to explore the effects of phosphodiesterase type 5 inhibitors (PDE5i), soluble guanylate cyclase stimulators (sGCs), endothelin receptor antagonists (ERAs), and angiotensinogen inhibitors (AGTis) on a range of CKM outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Mendelian randomization (MR), summary-based MR (SMR), and colocalization analyses were applied to assess the drug effect on coronary artery disease (CAD), myocardial infarction (MI), ischaemic stroke, atrial fibrillation (AF), heart failure (HF), type 2 diabetes (T2D), and chronic kidney disease (CKD). Genetic association and gene expression summary data were obtained from the largest European-ancestry genome-wide association studies (GWAS) and the genotype-tissue expression version 8 for 29 tissues relevant to the outcomes' pathophysiology.<\/jats:p>\n                    <jats:p>Genetically predicted systolic blood pressure (SBP) reduction was associated with reduced risks of all outcomes. PDE5i was associated with reduced risks of CAD (OR per 10-mmHg decrease in SBP: 0.348[95% confidence interval (CI): 0.199\u20130.607]) and ischaemic stroke (0.588[0.453\u20130.763]). sGCs showed protective effects against CAD (0.332[0.236\u20130.469]), MI (0.238[0.168\u20130.337]), and CKD (0.55[0.398\u20130.761]). ERA and AGTi showed protective effects against CAD and ischaemic stroke. SMR and colocalization supported the association of gene expression levels of GUCY1A3 and PDE5A with CAD and MI risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study highlights the potential of PDE5i, sGCs, ERA, and AGTi in reducing cardiovascular and renal risks. These findings underscore the necessity for targeted clinical trials to validate the efficacy and safety of these therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf015","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T15:21:41Z","timestamp":1739546501000},"page":"264-274","source":"Crossref","is-referenced-by-count":8,"title":["Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study"],"prefix":"10.1093","volume":"11","author":[{"given":"Nhu Ngoc","family":"Le","sequence":"first","affiliation":[{"name":"BHF Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tran Quoc Bao","family":"Tran","sequence":"additional","affiliation":[{"name":"BHF Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4839-5462","authenticated-orcid":false,"given":"John","family":"McClure","sequence":"additional","affiliation":[{"name":"BHF Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7312-7078","authenticated-orcid":false,"given":"Dipender","family":"Gill","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London Department of Epidemiology and Biostatistics, , London W2 1PG ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandosh","family":"Padmanabhan","sequence":"additional","affiliation":[{"name":"BHF Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"2025050208020694000_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2025050208020694000_bib2","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2025050208020694000_bib3","doi-asserted-by":"crossref","first-page":"5467","DOI":"10.1111\/bph.14920","article-title":"Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease","volume":"177","author":"Tzoumas","year":"2020","journal-title":"Br J Pharmacol"},{"key":"2025050208020694000_bib4","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2025050208020694000_bib5","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","article-title":"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial","volume":"400","author":"Schlaich","year":"2022","journal-title":"Lancet"},{"key":"2025050208020694000_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jchf.2022.06.005","article-title":"Angiotensinogen: more than its downstream products: evidence from population studies and novel therapeutics","volume":"10","author":"Kahlon","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025050208020694000_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N Engl J Med"},{"key":"2025050208020694000_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","article-title":"Mendelian randomization in cardiometabolic disease: challenges in evaluating causality","volume":"14","author":"Holmes","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2025050208020694000_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Davey Smith","year":"2003","journal-title":"Int J Epidemiol"},{"key":"2025050208020694000_bib10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ng.3538","article-title":"Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets","volume":"48","author":"Zhu","year":"2016","journal-title":"Nat Genet"},{"key":"2025050208020694000_bib11","doi-asserted-by":"crossref","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","article-title":"Bayesian test for colocalisation between pairs of genetic association studies using summary statistics","volume":"10","author":"Giambartolomei","year":"2014","journal-title":"PLoS Genet"},{"key":"2025050208020694000_bib12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","article-title":"Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits","volume":"50","author":"Evangelou","year":"2018","journal-title":"Nat Genet"},{"key":"2025050208020694000_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0962280210394459","article-title":"Using multiple genetic variants as instrumental variables for modifiable risk factors","volume":"21","author":"Palmer","year":"2011","journal-title":"Stat Methods Med Res"},{"key":"2025050208020694000_bib14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.aaz1776","article-title":"The GTEx Consortium atlas of genetic regulatory effects across human tissues","volume":"369","author":"Aguet","year":"2020","journal-title":"Science"},{"key":"2025050208020694000_bib15","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"2025050208020694000_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7326\/M14-0488","article-title":"Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study","volume":"162","author":"Anderson","year":"2015","journal-title":"Ann Intern Med"},{"key":"2025050208020694000_bib17","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.07.059","article-title":"Usual blood pressure and risk of new-onset diabetes: evidence from 4.1 million adults and a meta-analysis of prospective studies","volume":"66","author":"Emdin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2025050208020694000_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/gepi.21965","article-title":"Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator","volume":"40","author":"Bowden","year":"2016","journal-title":"Genet Epidemiol"},{"key":"2025050208020694000_bib19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2025050208020694000_bib20","author":"Neale"},{"key":"2025050208020694000_bib21","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00125-021-05564-7","article-title":"Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling","volume":"64","author":"Karhunen","year":"2021","journal-title":"Diabetologia"},{"key":"2025050208020694000_bib22","doi-asserted-by":"crossref","first-page":"e34408","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","author":"Hemani","year":"2018","journal-title":"eLife"},{"key":"2025050208020694000_bib23","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/ije\/dyx034","article-title":"MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data","volume":"46","author":"Yavorska","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2025050208020694000_bib24","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/genes13071226","article-title":"Unravelling the distinct effects of systolic and diastolic blood pressure using Mendelian randomisation","volume":"13","author":"Le","year":"2022","journal-title":"Genes (Basel)"},{"key":"2025050208020694000_bib25","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Prospective studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"2025050208020694000_bib26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/CIRCULATIONAHA.116.024152","article-title":"Functional characterization of the GUCY1A3 coronary artery disease risk locus","volume":"136","author":"Kessler","year":"2017","journal-title":"Circulation"},{"key":"2025050208020694000_bib27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1,000 genomes-based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"2025050208020694000_bib28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/heartjnl-2017-312865","article-title":"Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?","volume":"104","author":"Hutchings","year":"2018","journal-title":"Heart"},{"key":"2025050208020694000_bib29","article-title":"Phosphodiesterase 5 and its inhibitors with ischemic heart disease: a Mendelian randomization analysis and a real-world study","volume":"11","author":"Xiao","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025050208020694000_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"2025050208020694000_bib31","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41588-018-0171-3","article-title":"Biobank-driven genomic discovery yields new insight into atrial fibrillation biology","volume":"50","author":"Nielsen","year":"2018","journal-title":"Nat Genet"},{"key":"2025050208020694000_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41467-019-13690-5","article-title":"Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure","volume":"11","author":"Shah","year":"2020","journal-title":"Nat Commun"},{"key":"2025050208020694000_bib33","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41588-022-01233-6","article-title":"Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants","volume":"54","author":"Aragam","year":"2022","journal-title":"Nat Genet"},{"key":"2025050208020694000_bib34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-022-05165-3","article-title":"Stroke genetics informs drug discovery and risk prediction across ancestries","volume":"611","author":"Mishra","year":"2022","journal-title":"Nature"},{"key":"2025050208020694000_bib35","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41588-022-01058-3","article-title":"Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation","volume":"54","author":"Mahajan","year":"2022","journal-title":"Nat Genet"},{"key":"2025050208020694000_bib36","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41588-019-0407-x","article-title":"A catalog of genetic loci associated with kidney function from analyses of a million individuals","volume":"51","author":"Wuttke","year":"2019","journal-title":"Nat Genet"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf015\/61934566\/pvaf015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/3\/264\/61934566\/pvaf015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/3\/264\/61934566\/pvaf015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:33:05Z","timestamp":1746178385000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/3\/264\/8019777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,17]]},"published-print":{"date-parts":[[2025,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf015","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,2,17]]}}}